2.4.0.80007 - Disclosure - 2012 PRIVATE PLACEMENTtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001402785duration2013-01-01T00:00:002013-06-30T00:00:001true 1fpmi_NotesToFinancialStatementsAbstractfpmi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes to Financial Statements2false 2fpmi_PrivatePlacement2012TextBlockfpmi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00On November 19, 2012, the Company conducted a private placement offering and raised aggregate gross proceeds of $1,546,250 upon the sale of 1,819,119 shares of common stock at a price per share of $0.85 (the 2012 Private Placement).  For each share of common stock purchased, the investors received a warrant to purchase a share of the Companys common stock at an exercise price of $0.90 per share and a term of one year.  Net proceeds amounted to $1,360,572 after deducting offering expenses.    Brookline Group LLC served as the placement agents in connection with the 2012 Private Placement. Brookline received cash fees of $123,700 and 181,912 placement agent warrants to purchase shares of the Companys common stock at a price per share of $0.85 and a term of five years.  The fair value of the placement agent warrants was approximately $62,000 and were recorded as both a debit and credit to additional paid-in capital as a stock issuance cost.   All of the Investors represented that they were accredited investors, as that term is defined in Rule 501(a) of Regulation D under the Securities Act, and the sale of the securities was made in reliance on exemptions provided by Regulation D and Section 4(2) of the Securities Act of 1933, as amended.   In connection with the closing of the 2012 Private Placement, the Company entered into a registration rights agreement with the investors agreeing to file a registration statement within 30 days of the closing and to have the registration statement declared effective within 150 days of the closing, if the registration statement is not subject to a full review and within 180 days of the closing if the registration statement is subject to a full review.   The Company filed a registration statement with the SEC on December 21, 2012, which was declared effective by the SEC on December 31, 2012.falsefalsefalsenonnum:textBlockItemTypenaCustom element.No definition available.false0Note 2. PRIVATE PLACEMENT 2012false2012 PRIVATE PLACEMENTUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://flouropharmamedical.com/role/PrivatePlacement12